Wearable Anticancer Drug Delivery Approved, Recalculating the Time Cost of Myeloma Treatment
The FDA has approved Sanofi’s Sarclisa Escena, extending an existing multiple myeloma antibody therapy from long in-clinic infusions to subcutaneous injection and delivery through an on-body injector; this is not the arrival of a new drug, but a systemic compression of the cancer care workflow.